Healthcare
Sensorium – SUCCESS PAGE – April 8, 2025
The company’s AI-powered drug development program has the potential to uncover treatments for multiple diseases and impact millions of lives.
The company’s AI-powered drug development program has the potential to uncover treatments for multiple diseases and impact millions of lives.
The company’s AI-powered drug development program has the potential to uncover treatments for multiple diseases and impact millions of lives.
Nordicus has successively completed its first toxicity study for Orocidin QR-01, a novel treatment for aggressive periodontitis.
Nordicus has successively completed its first toxicity study for Orocidin QR-01, a novel treatment for aggressive periodontitis.
An innovative, clinical stage, drug development company that is creating a potential novel treatment for degenerative eye disease
An innovative, clinical stage, drug development company that is creating a potential novel treatment for degenerative eye disease
Angiex is developing first-in-class Nuclear-Delivered Antibody-Drug Conjugates to make cancer less lethal.
Angiex is developing first-in-class Nuclear-Delivered Antibody-Drug Conjugates to make cancer less lethal.
A biotech company developing a platform of novel antibodies and ADCs to treat life-threatening cancers including leukemia and lymphoma
A biotech company developing a platform of novel antibodies and ADCs to treat life-threatening cancers including leukemia and lymphoma
ZYUS Life Sciences (CVE: ZYUS) has developed a new compound that treats chronic pain effectively without opioids.
ZYUS Life Sciences (CVE: ZYUS) has developed a new compound that treats chronic pain effectively without opioids.